BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

The treatment of multiple myeloma (MM) has entered into a new era of immunotherapy. Novel immunotherapies will significantly improve patient outcome via simultaneously targeting malignant plasma cell (PC) and reversing immunocompromised bone marrow (BM) microenvironment. B-cell maturation antigen (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Shih-Feng, Lin, Liang, Xing, Lijie, Li, Yuyin, Yu, Tengteng, Anderson, Kenneth C, Tai, Yu-Tzu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352710/
https://www.ncbi.nlm.nih.gov/pubmed/32516895
http://dx.doi.org/10.3390/cancers12061473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352710/
https://www.ncbi.nlm.nih.gov/pubmed/32516895
http://dx.doi.org/10.3390/cancers12061473

Ejemplares similares